Literature DB >> 14984474

Sanfilippo B syndrome: molecular defects in Greek patients.

C Beesley1, M Moraitou, B Winchester, K Schulpis, E Dimitriou, H Michelakakis.   

Abstract

Sanfilippo syndrome type B [mucopolysaccharidosis IIIB (MPS IIIB] is the most prevalent type of MPS III in Greece, accounting for 81% of all MPS III cases diagnosed at the Institute of Child Health (Athens) over the last 20 years. The majority of the patients originated from East Central/Central Greece, Thessaly, and Macedonia. We present the results of mutation analysis in 21 Greek patients from 18 different families, all of whom had the severe form of the disorder. Patients were initially screened for five previously known mutations by restriction enzyme digestion of polymerase chain reaction products. Unknown mutations were identified by single-strand conformation polymorphism analysis and DNA sequencing and were confirmed by restriction enzyme analysis. Seven previously described mutations (Y140C, R626X, 503-512del, H414R, G292R, 334del25, and E452K) and four novel mutations (P516L, L242P, E446K, and R482Q) were identified. Expression of the latter and H414R showed that they were all null activity mutations. Considerable genetic heterogeneity has been described in MPS IIIB patients of different origins. In our population, Y140C, H414R, and R626X account for approximately 70% of the studied alleles. Our findings, especially in combination with the origin of individual patients, can improve carrier detection and genetic counseling in affected families.

Entities:  

Mesh:

Year:  2004        PMID: 14984474     DOI: 10.1111/j.0009-9163.2004.00210.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  9 in total

1.  Molecular defects in Sanfilippo syndrome type B (mucopolysaccharidosis IIIB).

Authors:  C E Beesley; M Jackson; E P Young; A Vellodi; B G Winchester
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Epidemiology of mucopolysaccharidoses.

Authors:  Shaukat A Khan; Hira Peracha; Diana Ballhausen; Alfred Wiesbauer; Marianne Rohrbach; Matthias Gautschi; Robert W Mason; Roberto Giugliani; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-05-26       Impact factor: 4.797

3.  Ensemble variant interpretation methods to predict enzyme activity and assign pathogenicity in the CAGI4 NAGLU (Human N-acetyl-glucosaminidase) and UBE2I (Human SUMO-ligase) challenges.

Authors:  Yizhou Yin; Kunal Kundu; Lipika R Pal; John Moult
Journal:  Hum Mutat       Date:  2017-06-27       Impact factor: 4.878

4.  Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype.

Authors:  Marlies J Valstar; Hennie T Bruggenwirth; Renske Olmer; Ron A Wevers; Frans W Verheijen; Ben J Poorthuis; Dicky J Halley; Frits A Wijburg
Journal:  J Inherit Metab Dis       Date:  2010-09-18       Impact factor: 4.982

Review 5.  Sanfilippo syndrome: a mini-review.

Authors:  M J Valstar; G J G Ruijter; O P van Diggelen; B J Poorthuis; F A Wijburg
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

6.  Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIB.

Authors:  O L M Meijer; L Welling; M J Valstar; L H Hoefsloot; H T Brüggenwirth; A T van der Ploeg; G J G Ruijter; T Wagemans; F A Wijburg; N van Vlies
Journal:  J Inherit Metab Dis       Date:  2016-02-23       Impact factor: 4.982

7.  The Neurobehavioral Phenotype in Mucopolysaccharidosis Type IIIB: an Exploratory Study.

Authors:  E Shapiro; K King; A Ahmed; K Rudser; R Rumsey; B Yund; K Delaney; I Nestrasil; C Whitley; M Potegal
Journal:  Mol Genet Metab Rep       Date:  2016-03-01

Review 8.  Epidemiology of Mucopolysaccharidoses Update.

Authors:  Betul Çelik; Saori C Tomatsu; Shunji Tomatsu; Shaukat A Khan
Journal:  Diagnostics (Basel)       Date:  2021-02-10

9.  A rapid and sensitive method for measuring N-acetylglucosaminidase activity in cultured cells.

Authors:  Victor Mauri; Parisa Lotfi; Laura Segatori; Marco Sardiello
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.